Innate Pharma SA (Euronext Paris: IPH; NASDAQ: IPHA) announced that interim results from its MATISSE Phase 2 study will be ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE